NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes. This study, will look into how safe the new medicine NNC0519-0130 is, and we will measure its concentrations in the blood and look at its effects. This study will last for a maximum of 22 weeks and Japanese and Non-Japanese male participants will be included.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
22
Administered subcutaneously.
Administered subcutaneously.
SOUSEIKAI Sumida Hospital
Tokyo, Japan
AUC0-24h,0130, SS: Area Under the NNC0519-0130 Plasma Concentration-Time Curve After the Last Dose in Each Treatment Period
Measured in h\*nmol/L.
Time frame: From pre-dose until 24 hours post-dose relative to last dose in each treatment period
Cmax,0130, SS: Maximum Plasma Concentration of NNC0519- 0130 After the Last Dose in Each Treatment Period
Measured in nmol/L.
Time frame: From pre-dose until 24 hours post-dose relative to last dose in each treatment period
Number of Treatment Emergent Adverse Events (TEAEs)
Measured as number of events.
Time frame: From time of dosing (day 1) until completion of the follow-up visit (day 105)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.